108 related articles for article (PubMed ID: 23639286)
21. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
22. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension.
Liu J; Liu ZQ; Yu BN; Xu FH; Mo W; Zhou G; Liu YZ; Li Q; Zhou HH
Clin Pharmacol Ther; 2006 Jul; 80(1):23-32. PubMed ID: 16815314
[TBL] [Abstract][Full Text] [Related]
23. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.
Bijl MJ; Visser LE; van Schaik RH; Kors JA; Witteman JC; Hofman A; Vulto AG; van Gelder T; Stricker BH
Clin Pharmacol Ther; 2009 Jan; 85(1):45-50. PubMed ID: 18784654
[TBL] [Abstract][Full Text] [Related]
24. Inhibition by metoprolol of the antihypertensive effect of aspirin in young rats.
Tuttle RS; Banziger V; Patel S; Northrup N
J Pharmacol Exp Ther; 1985 Jul; 234(1):166-71. PubMed ID: 2989503
[TBL] [Abstract][Full Text] [Related]
25. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
26. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Sehnert AJ; Daniels SE; Elashoff M; Wingrove JA; Burrow CR; Horne B; Muhlestein JB; Donahue M; Liggett SB; Anderson JL; Kraus WE
J Am Coll Cardiol; 2008 Aug; 52(8):644-51. PubMed ID: 18702968
[TBL] [Abstract][Full Text] [Related]
27. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo pharmacodynamic properties of metoprolol in fructose-fed hypertensive rats.
Di Verniero CA; Silberman EA; Mayer MA; Opezzo JA; Taira CA; Höcht C
J Cardiovasc Pharmacol; 2008 Jun; 51(6):532-41. PubMed ID: 18475202
[TBL] [Abstract][Full Text] [Related]
29. β(1)-adrenergic receptor polymorphisms and response to β-blockade in the African-American study of kidney disease and hypertension (AASK).
Lee J; Aziz H; Liu L; Lipkowitz M; O'Connor DT; Richard E; Brophy V; Wassel CL; Blantz R; ; Bhatnagar V
Am J Hypertens; 2011 Jun; 24(6):694-700. PubMed ID: 21415838
[TBL] [Abstract][Full Text] [Related]
30. β-blockers interfere with cell homing receptors and regulatory proteins in a model of spontaneously hypertensive rats.
Eibel B; Kristochek M; Peres TR; Dias LD; Dartora DR; Casali KR; Kalil RAK; Lehnen AM; Irigoyen MC; Markoski MM
Cardiovasc Ther; 2018 Aug; 36(4):e12434. PubMed ID: 29752864
[TBL] [Abstract][Full Text] [Related]
31. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.
Rau T; Wuttke H; Michels LM; Werner U; Bergmann K; Kreft M; Fromm MF; Eschenhagen T
Clin Pharmacol Ther; 2009 Mar; 85(3):269-72. PubMed ID: 19037197
[TBL] [Abstract][Full Text] [Related]
32. Cross-talk between cardiac kappa-opioid and beta-adrenergic receptors in developing hypertensive rats.
Yu XC; Wang HX; Zhang WM; Wong TM
J Mol Cell Cardiol; 1999 Mar; 31(3):597-605. PubMed ID: 10198190
[TBL] [Abstract][Full Text] [Related]
33. Changes in the in vitro pharmacodynamic properties of metoprolol in atria isolated from spontaneously hypertensive rats.
Di Verniero C; Höcht C; Opezzo JA; Taira CA
Clin Exp Pharmacol Physiol; 2007 Mar; 34(3):161-5. PubMed ID: 17250633
[TBL] [Abstract][Full Text] [Related]
34. Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor.
Maack C; Böhm M; Vlaskin L; Dabew E; Lorenz K; Schäfers HJ; Lohse MJ; Engelhardt S
Circulation; 2003 Jul; 108(3):348-53. PubMed ID: 12847069
[TBL] [Abstract][Full Text] [Related]
35. Cytochrome P450 2D6 phenotype and genotype in hypertensive patients on long-term therapy with metoprolol.
Duricova J; Perinova I; Jurckova N; Jeziskova I; Kacirova I; Grundmann M
Bratisl Lek Listy; 2013; 114(4):206-12. PubMed ID: 23514553
[TBL] [Abstract][Full Text] [Related]
36. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure.
Sharp CF; Gardiner SJ; Jensen BP; Roberts RL; Troughton RW; Lainchbury JG; Begg EJ
Pharmacogenomics J; 2009 Jun; 9(3):175-84. PubMed ID: 19365402
[TBL] [Abstract][Full Text] [Related]
37. Paroxetine Attenuates Cardiac Hypertrophy Via Blocking GRK2 and ADRB1 Interaction in Hypertension.
Sun X; Zhou M; Wen G; Huang Y; Wu J; Peng L; Jiang W; Yuan H; Lu Y; Cai J
J Am Heart Assoc; 2021 Jan; 10(1):e016364. PubMed ID: 33372534
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomics of heart failure: a systematic review.
Mottet F; Vardeny O; de Denus S
Pharmacogenomics; 2016 Nov; 17(16):1817-1858. PubMed ID: 27813451
[TBL] [Abstract][Full Text] [Related]
39. Effect of beta-adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats.
Fiordaliso F; De Angelis N; Bai A; Cuccovillo I; Salio M; Serra DM; Bianchi R; Razzetti R; Latini R; Masson S
Life Sci; 2007 Sep; 81(12):951-9. PubMed ID: 17825849
[TBL] [Abstract][Full Text] [Related]
40. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.
Ismail R; Teh LK
J Clin Pharm Ther; 2006 Feb; 31(1):99-109. PubMed ID: 16476126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
